Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Guy Laurent, MD, PhD, Sylvie Lafaye de Micheaux, MD, Philippe Solal-Celigny, MD, Pierre Soubeyran, MD, PhD, Vincent Delwail, Hervé Ghesquières, MD, Catherine Thieblemont, MD, Eric Jourdan, MD, PhD, Lucile Beautier, Fabien Audibert, Patrick Squiban, MD, Helene Sicard, PhD, Jean-Francois Rossi, MD, PhD

Blood (2009) 114 (22): 1649.

https://doi.org/10.1182/blood.V114.22.1649.1649

Published: 2009

Journal Articles

Complete Response After High-Dose Methotrexate-Based Chemotherapy as a Major Prognostic Factor for Primary CNS Lymphoma: An Exploratory Analysis of the LNHCP93 Trial of the Groupe d'Etude Des Lymphomes De l'Adulte.

Blood (2009) 114 (22): 101.

https://doi.org/10.1182/blood.V114.22.101.101

Published: 2009

Journal Articles

Treatment of Primary CNS Lymphoma in the Elderly with High-Dose Methotrexate Containing Chemotherapy Followed Radiotherapy or Chemotherapy Alone Plus Deferred Radiotherapy: Evaluation of Modification of Treatment Modalities in Leon Berard Cancer Center.

Hervé Ghesquières, MD, Agathe Bajard, Gilles Albrand, MD, Khaoula Alaoui-Slimani, MD, Philippe Rey, MD, Catherine Sebban, MD, Marie Pierre Sunyack, MD, Emmanuel Jouanneau, MD, PhD, Francois Ducray, MD, Catherine Chassagne-Clement, MD, Pierre Biron, MD, Jean-Yves Blay, MD, PhD

Blood (2009) 114 (22): 2702.

https://doi.org/10.1182/blood.V114.22.2702.2702

Published: 2009

Journal Articles

A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vã9Vä2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data.

Guy Laurent, MD, PhD, Jean François Rossi, MD, PhD, Eric W Van Den Neste, MD, PhD, Fabien Audibert, Hervé Ghesquières, MD, Steven Le Gouill, MD, PhD, Pierre Feugier, MD, Helene Sicard, PhD, Sophie Ingoure, Elodie Soule, Sylvie Lafaye de Micheaux, MD

Blood (2008) 112 (11): 1002.

https://doi.org/10.1182/blood.V112.11.1002.1002

Published: 2008

Journal Articles

Lymphopenia Prior High-Dose Chemotherapy Is a Major Prognostic Factor for Severe Infectious Complication after Autologous Blood Stem Cell Transplantation for Lymphoma’s Patients.

Hervé Ghesquières, MD, Roch Houot, MD, Céline Ferlay, Catherine Sebban, MD, Thérèse Gargi, CRA, Irène Philip, MD, Pierre Biron, MD, Isabelle Ray-Coquard, MD, Jean-Yves Blay, MD,PhD

Blood (2006) 108 (11): 2984.

https://doi.org/10.1182/blood.V108.11.2984.2984

Published: 2006

Journal Articles

Comparison of Outcome of Unselected Patients with Diffuse Large B-Cell Lymphoma Diagnosed before and after Approval of Rituximab in France in This Indication.

Hervé Ghesquières, MD, Catherine Sebban, MD, Catherine Chassagne, MD, Liana Carausu, MD, Thérèse Gargi, CRA, Bertrand Favier, PhD, Irène Philip, MD, Jean Yves Blay, MD, PhD, Pierre Biron, MD

Blood (2005) 106 (11): 4766.

https://doi.org/10.1182/blood.V106.11.4766.4766

Published: 2005

NARROW

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Complete Response After High-Dose Methotrexate-Based Chemotherapy as a Major Prognostic Factor for Primary CNS Lymphoma: An Exploratory Analysis of the LNHCP93 Trial of the Groupe d'Etude Des Lymphomes De l'Adulte.

Treatment of Primary CNS Lymphoma in the Elderly with High-Dose Methotrexate Containing Chemotherapy Followed Radiotherapy or Chemotherapy Alone Plus Deferred Radiotherapy: Evaluation of Modification of Treatment Modalities in Leon Berard Cancer Center.

A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vã9Vä2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data.

Lymphopenia Prior High-Dose Chemotherapy Is a Major Prognostic Factor for Severe Infectious Complication after Autologous Blood Stem Cell Transplantation for Lymphoma’s Patients.

Comparison of Outcome of Unselected Patients with Diffuse Large B-Cell Lymphoma Diagnosed before and after Approval of Rituximab in France in This Indication.

Email alerts

ASH Publications

American Society of Hematology

Phase I/II Study of IPH1101, γσ T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Complete Response After High-Dose Methotrexate-Based Chemotherapy as a Major Prognostic Factor for Primary CNS Lymphoma: An Exploratory Analysis of the LNHCP93 Trial of the Groupe d'Etude Des Lymphomes De l'Adulte.

Treatment of Primary CNS Lymphoma in the Elderly with High-Dose Methotrexate Containing Chemotherapy Followed Radiotherapy or Chemotherapy Alone Plus Deferred Radiotherapy: Evaluation of Modification of Treatment Modalities in Leon Berard Cancer Center.

A Phase I/II Study of IPH1101 (BrHPP), Specific Agonist of Vã9Vä2 T Lymphocytes, in Combination with Rituximab Re-Treatment in Patients with Follicular Lymphoma. Interim Phase I Data.

Lymphopenia Prior High-Dose Chemotherapy Is a Major Prognostic Factor for Severe Infectious Complication after Autologous Blood Stem Cell Transplantation for Lymphoma’s Patients.

Comparison of Outcome of Unselected Patients with Diffuse Large B-Cell Lymphoma Diagnosed before and after Approval of Rituximab in France in This Indication.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only